David Moore (biologist)

Moore began work as a postdoctoral researcher in 1979 in the laboratory of Howard Goodman in the Department of Biochemistry and Biophysics at the University of California, San Francisco, where he studied the genetic sequence of human growth hormone and the DNA binding activity of the glucocorticoid receptor.^[8][9]

Moore joined the faculty of the Department of Genetics at Harvard Medical School in 1981, and became a founding member of the Department of Molecular Biology at Massachusetts General Hospital.^[1] There, Moore's research lab investigated the activity of thyroid hormone and its relation to growth hormone expression. In collaboration with P. Reed Larsen, he identified several novel thyroid hormone receptors.^[10][11]

In 1987, Moore, alongside other colleagues including Frederick M Ausbel, established the laboratory manual series Current Protocols in Molecular Biology, which was acquired by Wiley in 1995 and later expanded to include additional titles.^[12]

Moore published a series of studies beginning in 1994 identifying and describing the constitutive androstane receptor (CAR), a constitutively active nuclear receptor which senses and responds to endobiotic and xenobiotic substances.^[3][13]

In 1996, Moore and his lab identified the small heterodimer partner (SHP), an orphan nuclear receptor without DNA-binding activity which binds other proteins to regulate their activity.^[14] He found that SHP inhibits estrogen receptors as well as retinoid receptors.^[4][15] He later found that SHP regulates the circadian clock in mice.^[16]

In 1997, Moore was recruited to the Department of Molecular and Cellular Biology, then headed by Bert W. O'Malley, at Baylor College of Medicine in Houston, Texas. There, he identified the bile acid and xenobiotic ligands of farnesoid X-receptor, an orphan nuclear receptor he had first purified in 1995, and an upstream regulator of SHP.^[5][17] He also identified androstane metabolites and xenobiotics as ligands for CAR during this time.^[13][18]

The discovery of bile acid ligands for FXR led Moore and colleagues to demonstrate a strong link between nuclear hormone receptors and liver disease. He showed that disruption of CAR, FXR, and SHP leads to liver tumors,^[19][20][21] hepatomegaly,^[19][22] and fatty liver disease.^[23][24]

Moore became professor of the Department of Nutritional Sciences & Toxicology at the University of California, Berkeley in 2020, where he became department chair in 2022.^[2]

Moore's h-index is 110 and i10-index is 303, and his publications have been cited over 87,000 times as of August 2023 according to his Google Scholar page.^[25]

Moore has received many academic prizes for his work, including the Edwin B. Astwood Award from the Endocrine Society^[26] and the Transatlantic Medal from the Society for Endocrinology.^[27] Moore was elected to the National Academy of Sciences in 2019^[1] and in 2022 became a fellow at the American Association for the Advancement of Science.^[28]